Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017

Genetics Investing

Mesoblast (Nasdaq:MESO) provided the market with an update on its operational highlights and consolidated financial results for the six months ended December 31, 2017 (the half-year of FY2018). As quoted in the press release: Revenues in the half-year of FY2018 were significantly increased to US$14.6 million, compared with US$0.9 million in the corresponding period in …

Mesoblast (Nasdaq:MESO) provided the market with an update on its operational highlights and consolidated financial results for the six months ended December 31, 2017 (the half-year of FY2018).

As quoted in the press release:

Revenues in the half-year of FY2018 were significantly increased to US$14.6 million, compared with US$0.9 million in the corresponding period in 2017, an increase of US$13.7 million. Net cash outflows from operating activities for the half-year were reduced by US$11.2 million (24%), compared with the half-year of FY2017. The Company recorded a profit after tax of US$6.7 million, compared with a loss after tax of US$39.8 million for the comparative period.

Click here to read the full press release.

financial results mesoblast operational highlights profit us Genetics Investing